The pathway includes testing tumour tissue for defective MMR by either microsatellite instability (MSI) testing or immunohistochemistry (IHC) for the MMR proteins MLH1, PMS2, MSH2 and MSH6. This evidence concerns the gene PMS2 and neoplasm.